In summary, the novel PDE4 inhibitor APR showed significant efficacy on ischemic stroke outcomes by alleviating enhanced BBB permeability and neuroinflammation by inhibiting ROCK2. This evidence concerns the gene ROCK2 and ischemic stroke.